These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
262 related items for PubMed ID: 38281891
1. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L. Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891 [Abstract] [Full Text] [Related]
2. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L. BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [Abstract] [Full Text] [Related]
3. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M. Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337 [Abstract] [Full Text] [Related]
4. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, Hutton AC, Agrawal S, Amin A, Blazevski A, Chalasani V, Ho B, Nguyen A, Liu V, Lee J, Sheehan-Dare G, Kooner R, Coughlin G, Chan L, Cusick T, Namdarian B, Kapoor J, Alghazo O, Woo HH, Lawrentschuk N, Murphy D, Hofman MS, Stricker P. Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492 [Abstract] [Full Text] [Related]
5. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study. Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W. Theranostics; 2021 Dec; 11(17):8396-8411. PubMed ID: 34373749 [Abstract] [Full Text] [Related]
6. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. Tran V, Hong A, Sutherland T, Taubman K, Lee SF, Lenaghan D, Sethi K, Corcoran NM, Lawrentschuk N, Woo H, Tarlinton L, Bolton D, Spelman T, Thomas L, Booth R, Hegarty J, Perry E, Wong LM. BMJ Open; 2022 Sep 19; 12(9):e061815. PubMed ID: 36123093 [Abstract] [Full Text] [Related]
7. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI. Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L. BJU Int; 2019 Nov 19; 124 Suppl 1():42-49. PubMed ID: 31287613 [Abstract] [Full Text] [Related]
8. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. Kelly BD, Ptasznik G, Roberts MJ, Doan P, Stricker P, Thompson J, Buteau J, Chen K, Alghazo O, O'Brien JS, Hofman MS, Frydenberg M, Lawrentschuk N, Lundon D, Murphy DG, Emmett L, Moon D. Eur Urol Open Sci; 2023 Jul 19; 53():90-97. PubMed ID: 37441340 [Abstract] [Full Text] [Related]
9. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer. Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA. Eur Urol Oncol; 2023 Dec 19; 6(6):574-581. PubMed ID: 37230883 [Abstract] [Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Dec 19; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
11. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer. Privé BM, Israël B, Janssen MJR, van der Leest MMG, de Rooij M, van Ipenburg JA, Jonker M, Peters SMB, de Groot M, Zámecnik P, Hoepping A, Bomers JG, Gotthardt M, Sedelaar JPM, Barentsz JO, van Oort IM, Nagarajah J. Radiology; 2024 May 19; 311(2):e231879. PubMed ID: 38771185 [Abstract] [Full Text] [Related]
12. Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, Meijer D, de Bie K, Yaqub M, Windhorst BAD, Hendrikse HNH, Vis AN, Oprea-Lager DE. Eur J Nucl Med Mol Imaging; 2022 Apr 19; 49(5):1731-1742. PubMed ID: 34725727 [Abstract] [Full Text] [Related]
13. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Eur Urol Oncol; 2019 Mar 19; 2(2):166-173. PubMed ID: 31017093 [Abstract] [Full Text] [Related]
14. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. J Nucl Med; 2022 Nov 19; 63(11):1644-1650. PubMed ID: 35301240 [Abstract] [Full Text] [Related]
15. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Casale P, Pietro D, Bevilacqua G, Balzarini L, Buffi NM, Guazzoni G, Lazzeri M. Eur Urol Focus; 2021 Jul 19; 7(4):764-771. PubMed ID: 32312701 [Abstract] [Full Text] [Related]
16. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer. Pepe P, Pepe L, Cosentino S, Ippolito M, Pennisi M, Fraggetta F. Anticancer Res; 2022 Jun 19; 42(6):3011-3015. PubMed ID: 35641295 [Abstract] [Full Text] [Related]
17. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M. BJU Int; 2020 Jul 19; 126(1):83-90. PubMed ID: 31260602 [Abstract] [Full Text] [Related]
18. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. BJU Int; 2023 May 19; 131(5):588-595. PubMed ID: 36371669 [Abstract] [Full Text] [Related]
19. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ. Eur Urol Oncol; 2021 Aug 19; 4(4):635-644. PubMed ID: 32675047 [Abstract] [Full Text] [Related]
20. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A, Rasiah K, John N, Moon D, Frydenberg M, Yaxley J, Stricker P, Wong K, Coughlin G, Gianduzzo T, Kua B, Ho B, Nguyen A, Liu V, Lee J, Hsiao E, Sutherland T, Perry E, Fendler WP, Hope TA. J Nucl Med; 2024 Jan 02; 65(1):94-99. PubMed ID: 38050155 [Abstract] [Full Text] [Related] Page: [Next] [New Search]